NEW YORK (GenomeWeb) ­­– Vermillion reported after the close of the market on Thursday an 89 percent jump in its first quarter revenues

For the three months ended Sept, 30, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $623,000 from $330,000 in the year-ago quarter.

Product revenues were $581,000, up from $330,000 in Q3 2015. Service revenues from the company's Aspira IVD business was $42,000. Vermillion had no service revenues in Q3 2015 as Aspira IVD was not yet operating.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.